SOBR Safe Inc (SOBR): Make sure to get 0.70s and to keep avera...

befast · 2025-03-01T14:45:25.9700000Z

Make sure to get 0.70s and to keep averaging down, because all support levels seem to be unable to hold these days. I guess we will keep drifting until earnings are out. If not good, this one will tank, but could jump rather quickly if good and positive guidance

Play Episode

4min

Proactive - Interviews for investors

Southern Cross Gold reveals Sunday Creek scale

Southern Cross Gold Consolidated CEO Michael Hudson talked with Proactive at the AIM's Small and Midcap Conference about the company’s focus on gold and antimony exploration in Victoria, Australia, particularly at the Sundae Creek project. Hudson outlined the scale and significance of the discovery, describing it as “one of the most exciting gold discoveries globally… a rare tier one multi-million ounce high grade discovery.” The company is advancing exploration rapidly, with six drill rigs currently operating and plans to expand to eight. Hudson said the company has completed around 70km of drilling and estimates an exploration target of 2.2 to 3.2 million ounces gold equivalent, grading between 8.5 to 10.6 grams per tonne – all within just 5% of the identified trend. Antimony also plays a key role. Hudson explained that China and Russia dominate the global market and recent export bans have highlighted supply vulnerabilities: “You don't have a defense industry without it. And the Western world really doesn't have it. We've got it.” Hudson also reflected on the company’s recent inclusion in the All Ordinaries Index, following the merger of Canadian and Australian entities. He said it marks the first index entry for Southern Cross Gold Consolidated and is “a reflection on a business that's less than three years old.” #SouthernCrossGold #SundayCreek #GoldExploration #Antimony #ASX #MiningStocks #JuniorMiners #ResourceInvesting #MichaelHudson #AllOrdinaries #GoldAndAntimony #AustralianMining

Proactive - Interviews for investors

Actinogen targets $20B Alzheimer’s market with Xanamem

Actinogen Medical Ltd Managing Director and CEO Dr Stephen Gourlay talked with Proactive at the AIM's Small and Midcap conference about the company’s lead asset, Xanamem, and its development in Alzheimer’s disease and depression. Dr Gourlay explained that Xanamem is an oral, once-a-day drug designed to modulate cortisol levels in the brain without interfering with the body’s essential stress response. “We’ve also shown some positive data, you know, phase two and depression as well, which is very exciting because that validates its mechanism,” he said. He outlined the commercial opportunity in both Alzheimer’s and depression. While depression is more prevalent, the Alzheimer's market offers larger potential revenue. He noted that current treatments either have side effects or provide only temporary cognitive improvement, whereas Xanamem could modify the disease course with a better safety profile. Dr Gourlay discussed Actinogen’s recent momentum, including positive results in a depression trial, a number of peer-reviewed publications, and the upcoming interim analysis from its Alzheimer’s trial in Australia and the US. He said, “The upside from a positive Alzheimer’s trial is completely massive… a multi-billion dollar asset.” The company is currently trading below the total investment into drug development, which Dr Gourlay described as a compelling investment case. #Actinogen #Xanamem #AlzheimersResearch #DepressionTreatment #BiotechStocks #ClinicalTrials #Neuroscience #PharmaInnovation #ASX #ProactiveInvestors

Proactive - Interviews for investors

Thor Explorations says Douta-West discovery adds gold ounces for upcoming PFS

Thor Explorations Ltd (TSX-V:THX, AIM:THX, OTC:THXPF) CEO Segun Lawson talked with Proactive's Stephen Gunnion about progress at the Douta gold project in Senegal, with a specific focus on the Douta-West licence. Lawson outlined that Thor acquired the licence a year ago and has since been advancing drilling efforts there. He confirmed the company has now made a fresh discovery, which includes oxide, free-flowing, recoverable gold material. “These are wide intersections between 12 and 20 metres wide, with very good grades between 1.3 and just over 2 grams per ton,” Lawson said. He added that the anomaly runs for approximately two kilometres and could be a significant contributor to the overall economics of the project. Lawson noted that the next step is to fully drill the strike length of the discovery zone. This will allow the company to include the newly identified ounces into its mine plan and potentially enhance the preliminary feasibility study (PFS). He also highlighted that the company is not pursuing exploration for academic purposes, but rather with a clear intent to build and deliver value to shareholders. Lawson confirmed that following the completion of the drilling campaign, Thor will provide an updated timeline for the PFS. Watch the full interview for more insights, and don’t forget to like this video, subscribe to Proactive’s YouTube channel, and turn on notifications for future updates. #ThorExplorations #GoldDiscovery #MiningUpdate #SenegalMining #DrillResults #DoutaProject #GoldStocks #PFS #JuniorMining #ResourceExpansion

Proactive - Interviews for investors

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce final survival data from a Phase 2a clinical trial evaluating the company’s investigational immunotherapy in patients with stage III/IV non-small cell lung cancer (NSCLC) who had an inadequate response to immune checkpoint inhibitor (ICI) treatment. The study reported a median overall survival (mOS) of 24.5 months in 46 evaluable patients who received two courses of the investigational therapy. In a subset of patients who had progressive disease at baseline despite ICI treatment, mOS was 21.5 months. Historically, similar patients receiving standard-of-care chemotherapy have had mOS between 9.8 and 11.8 months, with published studies rarely exceeding 12 months. With a median follow-up of 32.4 months, the data demonstrated long-term survival benefits, with 37% of patients who had progressive disease despite ICI therapy still alive two years after treatment. Based on these positive results, Candel Therapeutics will continue advancing the development program, including preparations for a potential registrational trial in patients with non-squamous histology NSCLC. The U.S. Food and Drug Administration (FDA) has previously granted Fast Track Designation for the investigational therapy in combination with an antiviral agent and ICI therapy for patients with stage III/IV NSCLC who are resistant to first-line PD-(L)1 inhibitors and do not have activating molecular driver mutations or have progressed on targeted therapy. These findings support the therapy’s potential as a new treatment option for NSCLC patients with limited alternatives. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

Followers	4
Posts	526
Boards Moderated	0
Alias Born	08/06/2010

Volume:	232,299
Day Range:	0.4558 - 0.4745
Bid:	0.4641
Ask:	0.4698
Last Trade Time:	3:24:35 PM EDT
Total Trades:	555

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

SOBR Detailed Quote

Recent SOBR News

More SOBR News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent SOBR News

Go Ad-Free